Sexual HealthCarbapenems And Other Agents That Provide Broad-Spectrum Activity Are Preferred By Surveyed Physicians For The Treatment Of Intra-Abdominal Infections
Arlington Medical Res (AMR) and Decision Res find that surveyed physicians will increase prescribing of Wyeth"s Tygacil, Merck"s Invanz and Johnson & Johnson"s Doribax in the next five years for the treatment of intra-abdominal infections because of their potent broad-spectrum activity and efficacy against gram-negative and anaerobic organisms.
"Treatment for intra-abdominal infections is largely empiric," stated Lisa Arias, analyst at Decision Res. "A variety of organisms, particularly gram-negative aerobic bacteria and anaerobes, are documented in patients with an intra-abdominal infection. In fact, the leading attribute that physicians surveyed look for in a drug to treat intra-abdominal infections is its activity against anaerobes."
The new report entitled Hospital Anti-Infectives Insight Series: Intra-Abdominal Infections also finds that 96 percent of surveyed physicians cite a drug"s activity against anaerobes as the leading attribute in antibiotic selection. Intra-abdominal infections are often polymicrobial in nature and involve anaerobes specific to the etiology of the infection, so activity against these organisms is advantageous even without bacterial confirmation.
"Physicians also rank availability in intravenous formulation and a low propensity to induce resistance as other important drug attributes that influence their selection in antibiotics," added Ms. Arias. "While some agents with anaerobic and gram negative activity, such as carbapenems, address some of these attributes, no antibiotic captures all of the top most important attributes which leaves opportunity for novel products to differentiate themselves."
About Hospital Anti-Infectives Insight Series
AMR and Decision Res" Hospital Anti-Infectives Insight Series analyzes hospital antibiotic prescribing patterns using AMR"s comprehensive and highly detailed clinical data in conjunction with Decision Res" disease area knowledge, primary research and extensive understanding of emerging therapies and forecasts. These reports examine the reasons behind physicians" product preferences, factors driving hospital antibiotic prescribing patterns and receptivity to emerging antibiotics.
About AMR
AMR serves the market intelligence needs of the pharmaceutical and diagnostic imaging industries. Research includes clinical inpatient databases that directly link anti-infective drug with indication/procedure, formulary and stocking status tracking studies, drug purchasing audits and diagnostic imaging procedure volume/contrast media usage audits. AMR is a Decision Res, Inc. company.
About Decision Res
Decision Res is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate res and master their chosen markets. Decision Res is a Decision Res, Inc. company.
About Decision Res, Inc.
Decision Res, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions.
All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.
Decision Res